Tailoring quaternized starch as a non-viral carrier for gene delivery applications

被引:16
作者
Sieradzki, Rivka [1 ]
Traitel, Tamar [2 ]
Goldbart, Riki [2 ]
Geresh, Shimona [1 ]
Kost, Joseph [2 ]
机构
[1] Ben Gurion Univ Negev, Dept Biotechnol, IL-84105 Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Dept Chem Engn, IL-84105 Beer Sheva, Israel
关键词
polysaccharide; quaternized starch; non-viral carrier; gene therapy; MOLECULAR-WEIGHT; DRUG-DELIVERY; PLASMID DNA; IN-VITRO; THERAPY; TRANSFECTION; CHITOSAN; PROTAMINE; POLYSACCHARIDE; NANOPARTICLES;
D O I
10.1002/pat.3277
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Non-viral gene delivery systems have become increasingly desirable in both basic research and clinical settings as they overcome some of the problems associated with viral vectors. Presently, non-viral carriers used for gene transfer consist mostly of liposomal formulations and cationic polymers. Starch, which is a biodegradable, biocompatible, non-toxic, and water soluble polysaccharide, was evaluated for its potential as a non-viral gene delivery carrier, after modifying it to cationic starch (Q-starch) by means of quaternization. Q-starch synthesis was assessed by means of nuclear magnetic resonance, Fourier transform infrared spectroscopy, elemental analysis, and Kjeldahl method, demonstrating that all the chemical reactions occurred. The Q-starch potential to condense pDNA was evaluated by gel electrophoresis, dynamic light scattering, atomic force microscopy, and zeta potential, validating the formation of nano-sized, positively charged spherical complexes. Transfection efficiency experiments reveal that there are two barriers for efficient transfection: endosomal escape and complex de-complexation, while the latter appears to be the rate-limiting step. We propose that further improvement in transfection efficiency can be achieved by augmenting carrier lysosomotropic ability, as well as its ability to disconnect from the pDNA. Copyright (c) 2014 John Wiley & Sons, Ltd.
引用
收藏
页码:552 / 561
页数:10
相关论文
共 47 条
[31]  
Neumann U, 2002, STARCH-STARKE, V54, P449, DOI 10.1002/1521-379X(200210)54:10<449::AID-STAR2222449>3.0.CO
[32]  
2-R
[33]   Nonviral vectors in the new millennium: Delivery barriers in gene transfer [J].
Nishikawa, M ;
Huang, L .
HUMAN GENE THERAPY, 2001, 12 (08) :861-870
[34]   Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes [J].
Ogris, M ;
Walker, G ;
Blessing, T ;
Kircheis, R ;
Wolschek, M ;
Wagner, E .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :173-181
[35]  
Pack DW, 2000, BIOTECHNOL BIOENG, V67, P217, DOI 10.1002/(SICI)1097-0290(20000120)67:2<217::AID-BIT11>3.3.CO
[36]  
2-H
[37]   Cationic starch: an effective flocculating agent [J].
Pal, S ;
Mal, D ;
Singh, RP .
CARBOHYDRATE POLYMERS, 2005, 59 (04) :417-423
[38]   Low molecular weight protamine as an efficient and nontoxic gene carrier:: in vitro study [J].
Park, YJ ;
Liang, JF ;
Ko, KS ;
Kim, SW ;
Yang, VC .
JOURNAL OF GENE MEDICINE, 2003, 5 (08) :700-711
[39]   Galactosylated chitosan-graft-dextran as hepatocyte-targeting DNA carrier [J].
Park, YK ;
Park, YH ;
Shin, BA ;
Choi, ES ;
Park, YR ;
Akaike, T ;
Cho, CS .
JOURNAL OF CONTROLLED RELEASE, 2000, 69 (01) :97-108
[40]   Gene Therapy: A Pharmacokinetic/Pharmacodynamic Modelling Overview [J].
Parra-Guillen, Zinnia P. ;
Gonzalez-Aseguinolaza, Gloria ;
Berraondo, Pedro ;
Troconiz, Inaki F. .
PHARMACEUTICAL RESEARCH, 2010, 27 (08) :1487-1497